Side effects may include respiratory depression (decreased breathing), small pupils, sleepiness, and low blood pressure.[3] The risk of overdose with buprenorphine/naloxone (unless combined with other sedating substances) is exceedingly low, and lower than with methadone,[7] but people are more likely to stop treatment on buprenorphine/naloxone than methadone.[7] Buprenorphine (like methadone) is a treatment option during pregnancy.
At lower doses, buprenorphine results in the usual opioid effects; high doses beyond a certain level do not result in greater effects.[8] This is believed to result in a lower risk of overdose than some other opioids.[8] Naloxone is an opioid antagonist that competes with and blocks the effect of other opioids (including buprenorphine) if given by injection.[3] Naloxone is poorly absorbed when taken by mouth and is added to decrease the risk that people will misuse the medication by injection.[1] Misuse by injection or use in the nose still occurs, and more recently the efficacy of naloxone in preventing misuse by injection has been brought into question and preparations including naloxone could even be less safe than preparations containing solely buprenorphine.[3][9] Rates of misuse in the U.S. appear to be lower than with other opioids.[10]
The combination formulation was approved for medical use in the U.S. in 2002,[3][10][11] and in the European Union in 2017.[4] A generic version was approved in the U.S. in 2018.[12] In 2019, it was the 272nd most commonly prescribed medication in the U.S., with more than 1million prescriptions.[13]
Medical uses
Buprenorphine/naloxone is used for the treatment of opioid use disorder.[14] Long-term outcomes are generally better with use of buprenorphine/naloxone than attempts at stopping opioid use altogether.[7] This includes a lower risk of overdose with medication use.[7] Due to the high binding affinity and low activation at the opioid receptor, cravings and withdrawal for opioids are decreased while preventing a person from getting high and relapsing on another opioid. The combination of the two medications is preferred over buprenorphine alone for maintenance treatment due to the presence of naloxone in the formulation, which is believed to help discourage intravenous use.[14] However, the belief that the addition of naloxone provides this benefit has been called into question, and posters on drug-related online forums have stated that they were able to attain a high by injecting preparations of buprenorphine despite being combined with naloxone.[9]
Buprenorphine/naloxone is effective for treating opioid dependence and serves as a recommended first-line medication according to the U.S. National Institute on Drug Abuse.[10] The medication is an effective maintenance therapy for opioid dependence and has generally similar efficacy to methadone. Both treatments—buprenorphine/naloxone and methadone—are substantially more effective than abstinence-based treatment.[7][15] As of October 2023 prescribers no longer need a Drug Addiction Treatment Act (DATA 2000) waiver to prescribe buprenorphine/nalaxone for opioid dependence.[16] All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for opioid use disorder in their practice if permitted by applicable state law. The Substance Abuse and Mental Health Services Administration encourages practitioners to treat patients within their practices who require treatment for a substance use disorder. Because it may now be prescribed much more readily out of an office setting (as opposed to methadone, which requires specialized centers), buprenorphine/naloxone allows people more access to this medication and more freedom of administration. It also thus comes with more risks in this vulnerable population. Buprenorphine/naloxone may be recommended for socially stable people who use opioids who cannot retrieve medications from a center daily, who have another condition requiring regular primary care visits, or who have jobs or daily lives that require they maintain all their faculties and cannot take a sedating medication.[7] Buprenorphine/naloxone is also recommended over methadone for people at high risk of methadone toxicity, such as the elderly, those taking high doses of benzodiazepines or other sedating substances, concomitant alcohol use disorder, those with a lower level of opioid tolerance, and those at high risk of prolonged QT interval. It is also helpful to use the medication in combination with psychosocial support and counseling.[3][17]
Available forms
Buprenorphine/naloxone is available in sublingual formulations (that is, products that are dissolved under the tongue). There is no evidence that the tablet formulation is easier to divert and use in ways other than intended by the prescriber compared to the film formulation, or that the tablet formulation has a higher risk for accidental ingestion by children.[18] There are various pharmacokinetic differences between sublingual formulations.[19]
Side effects are similar to those of buprenorphine and other opioids.[17] In addition, naloxone can induce withdrawal symptoms in people who are chemically dependent on opioids.[17] The most common side effects (in order of most to least common) of sublingual tablets include headaches, opioid withdrawal syndrome, pain, nausea, increased sweating, and difficulty sleeping.[21] The most common side effects seen in film formulations are tongue pain, decreased sensation and redness in the mouth, headache, nausea, vomiting, excessive sweating, constipation, signs and symptoms of opioid withdrawal, sleeping difficulties, pain, and swelling of the extremities.[3] Post-approval, the most frequently reported side effects of buprenorphine/naloxone in sublingual strip form (i.e. Suboxone strips) are peripheral edema, stomatitis, glossitis, blistering of the mouth, and mouth ulcers (mouth sores).[22][23] Use of buprenorphine/naloxone may also increase the risk of developing certain dental problems (including tooth decay and tooth loss).[24][25][26]
Buprenorphine/naloxone has a milder side effect profile than methadone and limited respiratory effects, due to both agonist/antagonist effects. But buprenorphine/naloxone may be less safe than methadone in people with stable liver disease since it can elevate liver enzymes.[27]
When taken in excess, buprenorphine/naloxone can produce dysphoric symptoms for non-opioid-dependent/tolerant people because buprenorphine is a partial opioid agonist. The sublingual formulation of the buprenorphine/naloxone combination was designed to reduce the potential to inject the medication in comparison to buprenorphine alone. If the combination is taken sublingually, as directed, the addition of naloxone does not diminish buprenorphine's effects. When an opioid-dependent person dissolves and injects a combination sublingual tablet, it is believed that a withdrawal effect may be triggered because of naloxone's high parenteral bioavailability.[28] However, the efficacy of naloxone in preventing misuse by injection has more recently been brought into question and preparations including naloxone could even be less safe than preparations containing solely buprenorphine.[9] While this mechanism may act to deter intravenous injection, the Suboxone formulation can still produce an opioid agonist "high" if used sublingually by non-dependent persons, leading to opioid dependence.[28][29]
Interactions
Buprenorphine's sedating/narcotic effect is increased by other sedating substances, such as other opioids, benzodiazepines, first-generation antihistamines, alcohol, and antipsychotics. Opioids and especially benzodiazepines also increase the risk of potentially lethal respiratory depression.[17]
Strong inhibitors of the liver enzyme CYP3A4, such as ketoconazole, moderately increase buprenorphine concentrations; CYP3A4 inducers can theoretically decrease concentrations of buprenorphine.[3][17]
Pharmacology
Mechanism of action
Buprenorphine binds strongly to opioid receptors and acts as a pain-reducing medication in the central nervous system (CNS). It binds to the μ-opioid receptor with high affinity, which produces analgesic effects in the CNS. It is a partial μ-opioid receptor agonist and a weak κ-opioid receptor antagonist. As a partial agonist, buprenorphine binds and activates the opioid receptors, but has only partial efficacy at the receptor relative to a full agonist, even at maximal receptor occupancy. It is thus well-suited to treat opioid dependence, as it produces milder effects on the opioid receptor with lower dependence and habit-forming potential.
Naloxone is a pure opioid antagonist that competes with opioid molecules in the CNS and prevents them from binding to the opioid receptors.[15] Naloxone's binding affinity is highest for the μ-opioid receptor, then the δ-opioid receptor, and lowest for the κ-opioid receptor.[30] Naloxone has poor bioavailability, and is rapidly inactivated following oral administration.[31] When injected, it exerts its full effects.
The principle behind its function as a deterrent is as follows: when taken sublingually as prescribed, buprenorphine's effects at the opioid receptor dominate, while naloxone's effects are negligible due to the low oral absorption. But when someone attempts to misuse the medication via either injection or inhalation, the naloxone is intended to act as an antagonist and either reduce the opioid's euphoric effects or even precipitate withdrawal in those dependent on opioids.[15] This helps reduce the potential for deviating from the prescriber's intended use relative to buprenorphine, though it does not eradicate it.[32] One reason that naloxone might have limited efficacy as an abuse-deterrent is that buprenorphine binds more tightly to the mu-opioid receptor than naloxone.[32]
Pharmacokinetics
There are small differences in the pharmacokinetics between different sublingual buprenorphine/naloxone products.[19] These differences may require changes in dose when a person switches from one product to another.[19] The buprenorphine/naloxone sublingual film (e.g. trade name Suboxone) achieves higher buprenorphine maximum plasma concentrations (Cmax) and area under the curve (AUC, a measure of total drug exposure) than the original buprenorphine/naloxone sublingual tablets at equal doses.[19] For example, at a buprenorphine/naloxone dose of 8 mg/2 mg, the buprenorphine Cmax after a single dose of the original tablet formulation is around 3 ng/mL whereas that of the 8 mg/2 mg film formulation is around 3.55 ng/mL.[19] The Zubsolv trade name sublingual tablets have higher buprenorphine bioavailability than the original sublingual tablets, while the Bunavail trade name buccal films have the highest bioavailability.[19] For example, a single dose of Bunavail 4.2 mg/0.7 mg achieves a Cmax around 3.41 ng/mL.[19]
Naloxone is extensively inactivated by first-pass metabolism in the liver, meaning that the use of buprenorphine/naloxone as prescribed should not lead to active naloxone in the blood (which, as an opioid antagonist, would reverse the effect of buprenorphine or other opioids).
Society and culture
Cost
While the cost of the medication buprenorphine/naloxone is greater than buprenorphine alone, one analysis predicted the overall costs would be less in the United States due to a lower risk of misuse.[34]
Access in the United States
Before the Drug Addiction Treatment Act of 2000 (DATA), physicians were not allowed to prescribe narcotics to treat opioid dependence. People with narcotic dependence had to go to registered clinics to receive treatment. With DATA, Suboxone was the first medication approved for office-based treatment for opioid dependence.[1] Suboxone has thus become widely used as a replacement for methadone as it can be prescribed by doctors in their offices, while methadone can only be provided at specialized addiction centers, of which there are a limited number, often making access difficult. Integrating Medication-Assisted Treatment into outpatient primary care practices improves patient access to Suboxone.[35] Some physicians are also leading a movement to begin prescribing it out of the emergency department (ED), as some small studies have shown ED-initiated Suboxone to be effective with people more likely to remain in addiction treatment compared to those either referred to addiction treatment programs or those receiving just a brief intervention in the department.[36][37]
Access to Suboxone can be limited due to varying prior authorization requirements across different insurers. Prior authorization is used by insurance companies to limit certain medications' use by requiring approval before the insurance company will pay for them.[38] This can influence a person's financial access and adherence. Financial access is determined through prior authorization approval, which the prescriber must request before the person can start the medication. The time it takes to have the request approved can delay the person starting the medication. The prior authorization process can also affect adherence because approval is needed for every prescription. This presents the potential for a gap in treatment and withdrawal symptoms as the person waits for approval. Several insurance companies, as well as Medicaid in various states, have removed the use of prior authorization for Suboxone in an attempt to increase access to this treatment.[39]
Controversies
In July 2019, the British company Reckitt Benckiser Group (RB Group) and its current/former affiliated entities (notably Indivior, which split from RB Group in 2014) settled with the US Department of Justice (DOJ) regarding the sale and marketing of brand name Suboxone (buprenorphine/naloxone).[40] The non-prosecution agreement involves RB Group paying up to $1.4 billion, the largest settlement payment in U.S. history involving an opioid-class medication.[40] This record was surpassed in October 2020, when Purdue Pharma reached an $8 billion settlement for claims related to injuries and deaths caused by the opioid epidemic, which includes criminal fines, forfeiture, and civil damages.[41] The 2019 case alleged anti-competitive behavior by RB Group and Indivior surrounding the expiration of their regulatory exclusivity for Suboxone sublingual tablets.[42] The DOJ alleged that RB Group and Indivior employed a product hopping scheme (when a firm ceases production of a product upon expiration of regulatory exclusivity in favor of another product that still has regulatory exclusivity in order to prevent generic manufacturer competition) by misrepresenting that the Suboxone sublingual film formulation was safer than the sublingual tablet formulation because "children are less likely to be accidentally exposed to the film product".[42] There was no scientific evidence for that claim.[18] The company also sponsored a complaint to the FDA, expressing concern that buprenorphine/naloxone sublingual tablets (the very product they formerly produced) were unsafe, requesting that applications for regulatory approval of generic products by other pharmaceutical companies (their competitors) be rejected by the US Food and Drug Administration.[42]
References
^ abcd"Buprenorphine". www.samhsa.gov. 31 May 2016. Retrieved 3 December 2017.
^ ab"Buprenorphine for Chronic Pain: A Review of the Clinical Effectiveness". Canadian Agency for Drugs and Technologies in Health. 6 January 2017. PMID28727399.
^Strain EC, Stoller K, Walsh SL, Bigelow GE (March 2000). "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers". Psychopharmacology. 148 (4): 374–383. doi:10.1007/s002130050066. PMID10928310. S2CID10401443.
^Nestler EJ, Jonathan D, Hyman SE, Malenka RC (2009). Molecular neuropharmacology: a foundation for clinical neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 190–191, 287. ISBN9780071481274. OCLC273018757.
^Kirk JK, et al. (2020). "Launching a Medication-Assisted Treatment in an Outpatient Office-Based Practice." Journal of Primary Care & Community Health. https://doi.org/10.1177/2150132720940723
Este artículo o sección tiene referencias, pero necesita más para complementar su verificabilidad.Este aviso fue puesto el 2 de junio de 2020. La Falange Cubana Líder Antonio Avendaño y Alfonso Serrano VilariñoFundación 1°19362°2004 [1]Disolución 1940Ideología Anticomunismo NacionalsindicalismoAnticapitalismoPosición Extrema derechaPaís Cuba CubaColores Rojo NegroAfiliación internacional Servicio Exterior de FalangeSitio...
This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Punk Rock New York – news · newspapers · books · scholar · JSTOR (April 2012) (Learn how and when to remove this template message) 2007 compilation album by Reagan YouthPunk Rock New YorkCompilation album by Reagan YouthReleased2007GenrePunk rock, hardcore punkLength57:4...
This article is written like a personal reflection, personal essay, or argumentative essay that states a Wikipedia editor's personal feelings or presents an original argument about a topic. Please help improve it by rewriting it in an encyclopedic style. (March 2023) (Learn how and when to remove this template message) Leader works with teams or followers beyond their immediate self-interests to identify needed changeTransformational leadership is a theory of leadership where a leader works w...
Lindsay DuncanCBEDuncan after a performance of John Gabriel Borkman at the Brooklyn Academy of Music, 2011LahirLindsay Vere Duncan7 November 1950 (umur 73)Edinburgh, Midlothian, SkotlandiaPekerjaanAktrisTahun aktif1975–sekarangSuami/istriHilton McRaeAnak1 Lindsay Vere Duncan, CBE (lahir 7 November 1950) adalah seorang aktris Skotlandia. Di atas panggung, dia telah memenangkan dua Olivier Awards (untuk Les Liaisons Dangereuses dan Private Lives) dan Tony Award (untuk Private Lives)...
Félicien Rops, Pornokratès, 1878 Seorang Gadis Dekaden, karya Ramón Casas, 1899 Gerakan Dekaden adalah sebuah gerakan sastra dan artistik akhir abad ke-19, yang terpusat di Eropa Barat. Karya-karya seni Félicien Rops dan novel Joris-Karl Huysmans Against Nature (1884) dianggap menjadi contoh utama dari gerakan dekaden. Gerakan tersebut pertama kali berkembang di Prancis dan kemudian menyebar ke seluruh belahan Eropa dan Amerika Serikat.[1] Referensi ^ Dictionary of Critical Theory...
Este artículo o sección tiene referencias, pero necesita más para complementar su verificabilidad.Este aviso fue puesto el 2 de diciembre de 2021. Visita pastoral de Juan Pablo II a Ecuador Mural de Juan Pablo II con el pueblo ecuatorianoLocalizaciónPaís EcuadorDatos generalesTipo viaje apostólicoIngreso GratuitoÁmbito NacionalObjetivo Visita pastoral a SudaméricaHistóricoFecha Del 29 de enero al 1 de febrero de 1985Cronología ◄ Actual ► Visita del papa Francisco a Ecuador...
Гергард Кеппеннім. Gerhard KöppenНародився 17 травня 1918(1918-05-17)Кулен-Вендорф, Людвігслюст-Пархім, Мекленбург-Передня Померанія, НДРПомер 5 травня 1942(1942-05-05) (23 роки)Азовське море·загиблий у боюКраїна Німецька імперіяДіяльність льотчикУчасник Друга світова війнаВійськове зван
Tolmerus pyragra Klasifikasi ilmiah Kerajaan: Animalia Filum: Arthropoda Kelas: Insecta Ordo: Diptera Famili: Tipulidae Genus: Tolmerus Spesies: Tolmerus pyragra Tolmerus pyragra adalah spesies lalat yang tergolong famili Asilidae. Lalat ini juga merupakan bagian dari genus Tolmerus, ordo Diptera, kelas Insecta, filum Arthropoda, dan kingdom Animalia. Lalat ini mempunyai insting predator yang agresif dan makanannya utamanya adalah serangga lain. Referensi Bisby F.A., Roskov Y.R., Orrell T.M.,...
Two-song single by Pearl Jam Merkin BallEP by Pearl Jam featuring Neil YoungReleasedDecember 4, 1995 (1995-12-04)RecordedFebruary 1995StudioBad Animals (Seattle, Washington)Genre Alternative rock grunge Length10:52LabelEpicProducerBrett EliasonPearl Jam chronology Vitalogy(1994) Merkin Ball(1995) No Code(1996) I Got IdSingle by Pearl Jam featuring Neil Youngfrom the EP Merkin Ball B-sideLong RoadReleasedDecember 4, 1995RecordedFebruary 1995StudioBad Animals (Seattle, Washin...
Final Piala Winners Eropa 1981TurnamenPiala Winners Eropa 1980–1981 Dinamo Tbilisi Carl Zeiss Jena 2 1 Tanggal13 Mei 1981StadionRheinstadion, DüsseldorfWasitRiccardo Lattanzi (Italia)Penonton8.000← 1980 1982 → Final Piala Winners Eropa 1981 adalah pertandingan final ke-21 dari turnamen sepak bola Piala Winners Eropa untuk menentukan juara musim 1980–1981. Pertandingan ini mempertemukan tim Uni Soviet Dinamo Tbilisi dengan tim Jerman Timur Carl Zeiss Jena dan diselen...
Housing estate in Tseung Kwan O, Hong Kong For the town centre in Burnaby, British Columbia, see Metrotown, Burnaby. This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article may contain excessive or inappropriate references to self-published sources. Please help improve it by removing references to unreliable sources where they are used inappropriately. (September 2011) (Learn how and...
Small tectonic plate in the southern Bismarck Sea South Bismarck PlateApproximate surface projections of active tectonic plates. Key: South Bismarck Plate, Solomon Sea Plate, Trobriand Plate, Woodlark Plate, Active trench subduction boundaries, Inactive trench subduction boundaries, current spreading boundary. The Australian Plate to the southeast and the Pacific Plate to the northwest are not shown, but their...
Fictional character from Doctor Who The DoctorThe Eleventh DoctorDoctor Who characterMatt Smith as the Eleventh DoctorFirst regular appearanceThe Eleventh Hour (2010)Last regular appearanceThe Time of the Doctor (2013)Introduced bySteven MoffatPortrayed byMatt SmithPreceded byDavid TennantSucceeded byPeter CapaldiInformationTenure3 April 2010 – 25 December 2013No of series3Appearances39 stories (44 episodes)Companions Amy Pond Rory Williams River Song[1] Craig Owens[...
Daftar julukan kota di Hawaii ini mengandung samaran, julukan, dan slogan yang disematkan kepada beberapa kota di Hawaii (resmi dan tidak resmi) oleh pemerintah kota, masyarakat setempat, orang asing, badan pariwisata, atau kamar dagang. Julukan kota berperan sebagai perintis identitas lokal, membantu orang asing mengenali masyarakat setempat, atau mengajak orang berkunjung karena julukannya khas; mengangkat martabat daerah; dan mempersatukan masyarakat.[1] Julukan dan slogan yang ber...
Founder of the Zand Dynasty (c. 1705 – 1779) Karim Khan redirects here. For other uses, see Karim Khan (disambiguation). Karim Khan Zandکریم خان زندVakil ol-Ra'aya(Deputy of the People)Contemporary portrait of Karim Khan Zand.Vakil ol-Ra'aya of IranReign1751 – 1 March 1779SuccessorMohammad Ali Khan ZandBornc. 1705Pari, Safavid IranDied1 March 1779Shiraz, Zand IranBurialPars Museum (1779–1796, 1925–present)Golestan Palace (1796–1925)ConsortsKhadijeh BegumShakh-e Nab...
Cet article est une ébauche concernant le chemin de fer. Vous pouvez partager vos connaissances en l’améliorant (comment ?) selon les recommandations des projets correspondants. Consultez la liste des tâches à accomplir en page de discussion. Voiture « Saucisson » Voitures allégées État « Saucisson » Identification Surnom Saucisson Type voiture d'express Maître d’œuvre EIC Commande 1936 Construction 1936 à 1939 Nombre 55 Période de service 1938 à 1...
This article is about 1987 American horror film. For the British film directed by Danny Boyle, see Shallow Grave (1994 film). 1987 American filmShallow GraveDirected byRichard StylesScreenplay byGeorge FernandezProduced byBarry H. WaldmanStarring Tony March Lisa Stahl Tom Law CinematographyOrson OrchoaEdited byCarolyn HortonMusic byMason DaringProductioncompanyELF Productions[1]Distributed byPrism Entertainment[1]Release date September 25, 1987 (1987-09-25) Runn...
Non-military aircraft contracting with the US military to act as emergency transports Civil Reserve Air Fleet Active1952–presentCountry United StatesSize450 aircraft as of 2022Part ofAir Mobility CommandInsigniaCRAF emblemMilitary unit The Civil Reserve Air Fleet (CRAF) is part of the United States's mobility resources. Selected aircraft from U.S. airlines, contractually committed to Civil Reserve Air Fleet, support United States Department of Defense airlift requirements in emerg...
1954 Felber Möve The Möve 101 was a microcar with egg-shaped coupé bodywork based on a Felber Autoroller chassis. Ten cars were built in Vienna by a specialist coachbuilding company Hofmann & Moldrich in 1953.[1][2] Though the fully enclosed bodywork made from 0.8 mm aluminium plate was more sophisticated than that of the Felber, the car proved more expensive to produce and the heavier bodywork reduced performance and made the car less stable.[1][2]...
This article is about the post-2010 constituency covering the whole department. For the pre-2010 1st constituency, see Creuse's 1st constituency. Constituency of the National Assembly of France constituency of the CreuseinlineConstituency of the National Assembly of FranceCreuse in FranceDeputyCatherine CouturierLFIDepartmentCreuseCantonsEntire Department Politics of France Political parties Elections Previous Next You can help expand this article with text translated from the corresponding a...